There are two trials that I think are probably the most excited about. One of them is called the PEAK trial, and it was a ...

George: The phase 1/2 study is evaluating a new compound called DCC-3009. It is a drug that was designed specifically to work ...

A young woman was diagnosed with a rare stomach cancer just months after doctors shrugged off her symptoms as being 'women's ...

Traditionally, cancer diagnosis and prognosis rely heavily on histopathological examination, where tissue morphology is evaluated under the microscope. However, the molecular ...

A live webcast will be available on the Investors & Media page of Cogent’s website at investors.cogentbio.com. A replay of the webcast will be available approximately two hours after the completion of ...

Clinical study from Baylor College of Medicine demonstrates a favorable safety profile and up to 84.6% disease control rate in patients with ...

A young woman was diagnosed with a rare stomach cancer just months after doctors shrugged off her symptoms as being 'women's ...

A personal reflection on the promise and limits of CAR T therapy—its breakthroughs, failures, scientific bottlenecks, and what must change to truly save more lives.

Recent advances in cancer biology have revealed that refractory malignancies, such as castration-resistant prostate cancer, pancreatic ductal ...

Cancer therapy and synthetic biology are converging around a shared problem that has long frustrated oncologists and ...

A study led by researchers at Moffitt Cancer Center found that normal cells surrounding a tumor, known as cancer-associated ...

A novel tumor suppressor, BATF2, can be silenced by factors in the tumor microenvironment, leading to a reduced immune ...